Anti-Human EGFR (Cetuximab) – Dylight® 488
Anti-Human EGFR (Cetuximab) – Dylight® 488
Product No.: LT611
- -
- -
Product No.LT611 Clone C225 Target EGFR Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names ErbB-1; HER1; epidermal growth factor receptor Isotype Human IgG1κ Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human EGFR/ErbB1 Product Concentration 0.2 mg/ml Formulation This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Blue Laser (493 nm) RRIDAB_2893976 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Cetuximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? CyTOF® Additional Reported Applications For Relevant Conjugates ? B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Cetuximab. Clone C225 recognizes human EGFR. This product is for research use only. Background EGFR is a 170 kD transmembrane glycoprotein that is part of the ErbB family of receptors within the protein kinase superfamily. EGFR is one of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). EGFR is essential for various processes including controlling cell growth and differentiation and ductal development of the mammary glands. Ligand binding induces dimerization and autophosphorylation. It consists of a glycosylated extracellular domain which binds to EGF and an intracellular domain with tyrosine-kinase activity necessary for signal transduction. TGFα, vaccinia virus growth factor, and related growth factors can also bind to and signal through EGFR. Abnormal EGFR signaling has been implicated in inflammatory diseases such as psoriasis, eczema and atherosclerosis. Alzheimer's disease is linked with poor signaling of the EGFR and other receptor tyrosine kinases. Furthermore, over-expression of the EGFR is linked with the growth of various tumors. EGFR has been identified as an oncogene, a gene which in certain circumstances can transform a cell into a tumor cell, which has led to the therapeutic development of anticancer EGFR inhibitors. EGFR is a well-established target for both mAbs and specific tyrosine kinase inhibitors. Anti-Human EGFR (Cetuximab) utilizes the same variable regions from the therapeutic antibody Cetuximab making it ideal for research projects. Antigen Distribution EGFR is ubiquitously expressed and found in the plasma membrane. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars References & Citations1. Tortora, G. et al. (1999) Clin Cancer Res. 5(4):909-16. 2. Myers, J. et al. (2006) Clin Cancer Res. 12(2): 600–607. Technical Protocols Certificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
LT600 | |
LT603 | |
LT604 | |
LT611 | |
LT605 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
